SEC Form 4 · accession 0001562180-17-004013
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Jonas
Officer — President & CEO · Director
Period of report
Dec 21, 2017
Accepted (ET)
Dec 22, 2017 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 21, 2017 | M | 110,247 | $0.45 | A | 211,473 | D | |
| Common StockF2 | Dec 21, 2017 | S | 36,989 | $155.48 | D | 174,484 | D | |
| Common StockF3 | Dec 21, 2017 | S | 71,823 | $156.55 | D | 102,661 | D | |
| Common StockF4 | Dec 21, 2017 | S | 27,152 | $157.48 | D | 75,509 | D | |
| Common StockF5 | Dec 21, 2017 | S | 33,301 | $158.21 | D | 42,208 | D | |
| Common StockF6 | Dec 21, 2017 | S | 22,334 | $159.53 | D | 19,874 | D | |
| Common StockF7 | Dec 21, 2017 | S | 13,049 | $160.36 | D | 6,825 | D | |
| Common StockF8 | Dec 21, 2017 | S | 5,000 | $162.08 | D | 1,825 | D | |
| Common StockF9 | Dec 21, 2017 | S | 599 | $162.59 | D | 1,226 | D | |
| Common Stock | Dec 22, 2017 | M | 12,753 | $0.45 | A | 13,979 | D | |
| Common Stock | Dec 22, 2017 | S | 12,753 | $155.00 | D | 1,226 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F10 | $0.45 | Dec 21, 2017 | M | 110,247 | D | — | Aug 12, 2023 | Common Stock | 110,247 | 295,305 | D |
| Stock Option (Right to Buy)F10 | $0.45 | Dec 22, 2017 | M | 12,753 | D | — | Aug 12, 2023 | Common Stock | 12,753 | 282,552 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F10The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017, subject to continued service through such date.
- F2This transaction was executed in multiple trades at prices ranging from $155.00 USD to $155.99 USD. The price reported above reflects the weighted average sale price.
- F3This transaction was executed in multiple trades at prices ranging from $156.00 USD to $156.99 USD. The price reported above reflects the weighted average sale price.
- F4This transaction was executed in multiple trades at prices ranging from $157.00 USD to $157.99 USD. The price reported above reflects the weighted average sale price.
- F5This transaction was executed in multiple trades at prices ranging from $158.00 USD to $158.99 USD. The price reported above reflects the weighted average sale price.
- F6This transaction was executed in multiple trades at prices ranging from $159.00 USD to $159.99 USD. The price reported above reflects the weighted average sale price.
- F7This transaction was executed in multiple trades at prices ranging from $160.00 USD to $160.97 USD. The price reported above reflects the weighted average sale price.
- F8This transaction was executed in multiple trades at prices ranging from $161.43 USD to $162.41 USD. The price reported above reflects the weighted average sale price.
- F9This transaction was executed in multiple trades at prices ranging from $162.44 USD to $162.68 USD. The price reported above reflects the weighted average sale price.